Interesting RCC trials with Bristol Meyers
I don't know if you saw this in the news yesterday, but I found it interesting:
• Bristol-Myers Squibb (BMY). A combination of two immunotherapy drugs of the company, Opdivo and Yervoy, cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. The scale of the benefit provided by the two immune system-boosting drugs has been disclosed to experts attending the European Society for Medical Oncology (ESMO) congress in Madrid. Separately, researchers reported that Opdivo is a better and safer option than Yervoy for treating melanoma patients who have had surgery to remove disease.
Comments
-
Good results
Advancements in understanding and treating various types of cancer are increasing in frequency now but it still takes time.
I read the reuters article but I don't understand what this paragraph means for the claimed 37% cut in risk of death:
"In August, Bristol-Myers reported Opdivo and Yervoy failed to significantly outperform standard care in checking cancer progression, although there was a trend toward benefit."
Maybe it is something simple I am overlooking. Does the combination deliver a 37% cut in the risk of death or does it fail to significantly outperform standard care? Or are they not mutually exclusive?
0 -
BMS Trails
I understand that the Reuters press release is talking about publication of the results from the Checkmate 214 trial - see parallel discussion started by Lobbyist 0724, and follow his link to the actual BMS press release.
There are different reported outcomes for different groupings in the overall trial sample.
I have also responded to that posting with my own experience with these drugs (Yervoy is Ipilimumbab and Opdivo is Nivolumab). I am considered cured of the Stage 4 mRCC with which I was diagnosed in April 2015, although I am reluctant to take that as a certainty. I was always symptom free throughout my whole cancer experience, and was reasonably fit and healthy, other than what the sacns were telling us.
I am still receiving the Nivo as part of the trial although that may now change. I regard these drugs as having saved my life and am very happy to see that others can now get access to it.
I also think this is a perfect example of what science can achieve, despite the noise from some of the science sceptics out there.
0 -
Loud and clearfoxhd said:I hear you
I was in a phase one trial of nivo. Before it had a real name it was MDX-1107. It saved me too. 6 years ago.
...so I rarely post anymore, but I do creep in and read, pray for lots more than I speak about.I am also a phase I of the trial. I am still in the Sutent -Nivo arm of the trial. It will be 5 years in February that I have been taking the combo. Still here, still cancer free.
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 121.8K Cancer specific
- 2.8K Anal Cancer
- 446 Bladder Cancer
- 309 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 397 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 671 Leukemia
- 792 Liver Cancer
- 4.1K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 237 Multiple Myeloma
- 7.1K Ovarian Cancer
- 61 Pancreatic Cancer
- 487 Peritoneal Cancer
- 5.5K Prostate Cancer
- 1.2K Rare and Other Cancers
- 539 Sarcoma
- 730 Skin Cancer
- 653 Stomach Cancer
- 191 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards